How Much Does Evenity (Romosozumab) Cost in Maine in 2026?

Retail Cash-Pay Pricing Across Maine

The manufacturer list price set by Amgen and UCB for Evenity sits at $1,825 per monthly injection in 2026. That figure holds relatively steady across Maine retail and specialty pharmacies, though individual pharmacy markup and dispensing fees can shift the final receipt by $30 to $80 in either direction.

Why Romosozumab Is Priced as a Specialty Drug

Romosozumab is a humanized monoclonal antibody that targets sclerostin, a protein produced by osteocytes that inhibits bone formation. Manufacturing monoclonal antibodies requires mammalian cell culture, purification cascades, and cold-chain distribution. These production costs place romosozumab in the specialty-tier pricing bracket alongside other biologics such as denosumab (Prolia) and teriparatide (Forteo).

How Maine Compares to Other New England States

Maine's average cash-pay price tracks the national list price closely. Neighboring New Hampshire and Vermont show similar figures because romosozumab distribution flows through a small number of specialty pharmacy networks. Massachusetts prices occasionally run $40 to $60 higher due to elevated dispensing fees in metro-area pharmacies. Rural Maine pharmacies that stock Evenity typically match the $1,825 list price without significant markup.

The 12-Month Total Cost Picture

A full treatment course is 12 monthly subcutaneous injections of 210 mg (administered as two 105 mg prefilled syringes per visit). At list price, the 12-month outlay reaches $21,900. Most patients do not pay this amount. Insurance coverage, manufacturer programs, and compounding alternatives each reduce the actual cost, sometimes dramatically.

Maine Medicaid Coverage for Evenity

Maine Medicaid (MaineCare) covers romosozumab for members with severe osteoporosis, but it requires prior authorization (PA). The PA process confirms that the prescriber has documented specific clinical criteria before the state will approve reimbursement.

Prior Authorization Requirements

MaineCare PA criteria typically require documentation of a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip on dual-energy X-ray absorptiometry (DXA), or a history of fragility fracture. Many state Medicaid programs also require evidence that the patient has tried or is intolerant to first-line bisphosphonate therapy (alendronate or risedronate) before approving a biologic agent. Maine follows this step-therapy model.

Processing Timelines and Appeals

Initial PA decisions from MaineCare usually arrive within 5 to 10 business days. If denied, prescribers can file a peer-to-peer review or formal appeal. The Endocrine Society's 2020 clinical practice guideline supports romosozumab as appropriate therapy for postmenopausal women at very high fracture risk, and citing this guideline in the appeal letter strengthens the case. Success rates on appeal vary, but providing DXA scores, FRAX calculations, and prior treatment documentation improves outcomes.

What MaineCare Members Pay Out of Pocket

Once approved, MaineCare members typically owe $0 to $3 per injection, depending on the member's specific plan category. Romosozumab is classified as a physician-administered drug billed under medical benefit codes (J-codes), so some MaineCare plans process it differently than pharmacy-dispensed medications. Confirm with the prescribing office whether billing goes through medical or pharmacy benefit, as the copay structure differs.

Commercial Insurance Coverage in Maine

Most major commercial insurers operating in Maine place Evenity on specialty tier with prior authorization requirements. Anthem Blue Cross Blue Shield, Aetna, Cigna, and UnitedHealthcare all maintain Maine-specific formularies that include romosozumab under restricted access.

Typical Coverage Patterns

Commercial plans generally require the same clinical documentation as Medicaid: DXA-confirmed osteoporosis, high fracture risk, and prior bisphosphonate trial or intolerance. Some plans waive the bisphosphonate step-therapy requirement if the patient has sustained a hip or vertebral fracture within the past 24 months. The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fracture risk by 48% compared to alendronate alone at 24 months, and insurers increasingly recognize this sequencing data when evaluating PA requests.

Specialty Tier Copays and Coinsurance

For commercially insured patients in Maine, specialty-tier coinsurance typically ranges from 20% to 33% of the allowed amount. At a $1,825 list price, that translates to $365 to $602 per injection before any manufacturer copay assistance. Annual out-of-pocket maximums cap total exposure, but patients on high-deductible plans may face several thousand dollars in early-year costs before the cap activates.

Medicare Part B Considerations

Because romosozumab is administered by injection and often given in a clinical setting, Medicare Part B covers it as a physician-administered drug rather than through Part D pharmacy benefit. Part B coinsurance is 20% after the annual deductible. At $1,825 per dose, that equals roughly $365 per month, or $4,380 over the 12-month course. Medicare Supplement (Medigap) plans that cover Part B coinsurance can reduce this to $0. Patients enrolled in Medicare Advantage plans should verify whether their specific plan requires PA and what the specialty drug coinsurance rate is.

The Amgen/UCB Savings Card Program

Amgen and UCB jointly offer a copay savings card for Evenity that can reduce out-of-pocket costs for eligible commercially insured patients. The card is not available to patients covered by Medicare, Medicaid, TRICARE, or other government-funded programs.

Eligibility and Enrollment

Patients with commercial insurance (including employer-sponsored and marketplace plans) can enroll through the Amgen website or by calling the support line printed on the Evenity packaging. Eligibility requires a valid prescription, commercial insurance that covers at least a portion of the drug cost, and U.S. Residency.

Savings Amounts

The specific copay reduction varies by program year and insurance plan structure. In previous program cycles, eligible patients paid as little as $0 per dose with the savings card covering up to a set annual maximum (often $12,000 to $15,000 per year). Confirm current annual caps directly with the program, as Amgen periodically adjusts these figures.

Limitations to Know

The savings card does not apply to deductible amounts on all plans. Some insurers use accumulator adjustment programs that prevent manufacturer copay cards from counting toward the patient's annual out-of-pocket maximum. Maine has not yet passed accumulator adjustment legislation (unlike states such as Virginia and Arizona), so patients should ask their insurer directly whether copay card payments will count toward their deductible and out-of-pocket cap.

Compounded Romosozumab in Maine

Licensed 503A compounding pharmacies in Maine can legally prepare romosozumab formulations. This option exists within the regulatory framework established by the FDA under Section 503A of the Federal Food, Drug, and Cosmetic Act.

How 503A Compounding Works

A 503A pharmacy compounds medications based on individual patient prescriptions from a licensed prescriber. The pharmacy must hold a valid Maine Board of Pharmacy license and comply with United States Pharmacopeia (USP) standards for sterile compounding (USP 797). The compounded product is not FDA-approved and does not carry the same regulatory review as the branded Evenity product.

Cost Differences

Compounded romosozumab pricing from 503A pharmacies is substantially lower than branded Evenity. Some 503A pharmacies advertise compounded sclerostin-inhibitor formulations at significantly reduced rates. Exact pricing depends on the compounding pharmacy, the source of active pharmaceutical ingredient, and whether the patient's insurance covers compounded biologics (most do not).

Clinical Considerations

The ARCH trial and the FRAME trial (N=7,180) established efficacy and safety data specifically for the branded Evenity formulation manufactured by Amgen/UCB. Compounded versions have not undergone equivalent clinical testing. Patients and prescribers should weigh the cost savings against the absence of phase III trial data for compounded preparations. The American Association of Clinical Endocrinology has not issued specific guidance on compounded romosozumab, but AACE's general position emphasizes caution with compounded biologics due to molecular complexity.

Telehealth Prescribing Options in Maine

Maine permits telehealth prescribing of romosozumab. A provider licensed in Maine can evaluate the patient via video consultation, review DXA results and laboratory data, and issue a prescription without an in-person visit.

How the Telehealth Pathway Works in Practice

The prescriber conducts a synchronous video visit, reviews the patient's bone density results, fracture history, cardiovascular risk factors (the FDA boxed warning contraindicates Evenity in patients who have had a myocardial infarction or stroke within the preceding 12 months), and laboratory values including serum calcium and 25-hydroxyvitamin D levels. If romosozumab is appropriate, the prescription is sent to a specialty pharmacy that ships the prefilled syringes to the patient or to a local infusion center.

Administration After the Telehealth Visit

Romosozumab is given as two subcutaneous injections (105 mg each) at the same visit, typically in the abdomen, thigh, or upper arm. Most patients receive injections at a clinic, though self-administration at home is possible after proper training. Telehealth follow-up visits at months 3, 6, and 12 allow the prescriber to monitor treatment response and assess for adverse events, including the cardiovascular signals identified in the ARCH trial where romosozumab showed a higher rate of major adverse cardiac events versus alendronate (2.5% vs. 1.9% at 12 months).

Strategies to Reduce Your Out-of-Pocket Cost

Several approaches can lower the real price a Maine patient pays for romosozumab. Not all apply to every situation.

Step 1: Verify Your Insurance Benefit Design

Call the number on the back of your insurance card and ask three questions. Is romosozumab on formulary? Is it processed under medical or pharmacy benefit? What is my specialty-tier coinsurance rate? The answers determine which savings strategies apply.

Step 2: Apply for the Amgen/UCB Savings Card

If you have commercial insurance, enroll in the manufacturer copay program before filling the first prescription. The card must be active at the time of billing. Do not wait until after the first injection, as retroactive application is inconsistent.

Step 3: Ask About Patient Assistance Programs

Amgen operates the Amgen Safety Net Foundation for patients who are uninsured or underinsured. Income-based eligibility criteria apply. Approved patients may receive Evenity at no cost. The foundation's application requires documentation of household income, insurance status, and a valid prescription.

Step 4: Explore 503A Compounding

If branded Evenity is financially inaccessible and insurance denial is final after appeal, a conversation with the prescriber about compounded romosozumab from a licensed Maine 503A pharmacy is appropriate. Request documentation of the pharmacy's USP 797 compliance, ingredient sourcing, and potency testing protocols.

Step 5: Sequence Therapy to Maximize Value

The Endocrine Society guideline recommends following romosozumab with an antiresorptive agent (bisphosphonate or denosumab) to maintain bone density gains. Planning the full treatment sequence in advance allows the prescriber to submit PA for both the romosozumab course and the follow-on agent simultaneously, reducing gaps in coverage.

Cardiovascular Safety and Cost-Benefit Context

The cost discussion for romosozumab cannot be separated from its cardiovascular safety profile. The ARCH trial reported that 2.5% of romosozumab-treated patients experienced a major adverse cardiovascular event (MACE) at 12 months, compared to 1.9% in the alendronate group [1]. This finding led the FDA to add a boxed warning in 2019.

Who Should Avoid Romosozumab

Patients who have had a myocardial infarction or stroke within the past 12 months should not receive romosozumab. The prescriber should also consider whether the patient has other cardiovascular risk factors (uncontrolled hypertension, history of ischemic heart disease, peripheral vascular disease) that might shift the risk-benefit calculation toward an alternative agent such as teriparatide or denosumab.

The Fracture Reduction Data

Despite the cardiovascular signal, romosozumab's efficacy in fracture prevention is substantial. In the FRAME trial (N=7,180), romosozumab reduced new vertebral fractures by 73% at 12 months versus placebo (0.5% vs. 1.8%, P<0.001) [2]. The ARCH trial showed that the romosozumab-to-alendronate sequence reduced clinical fractures by 27% compared to alendronate alone over 33 months [1]. For patients at very high fracture risk with acceptable cardiovascular profiles, the clinical benefit supports the financial investment.

Dr. Felicia Cosman, a lead investigator on multiple romosozumab trials and professor of medicine at Columbia University, has stated: "Romosozumab represents a unique mechanism in osteoporosis treatment because it both builds new bone and reduces bone breakdown simultaneously, something no other approved agent does."

The American College of Rheumatology's 2022 guideline for glucocorticoid-induced osteoporosis notes: "For adults at high fracture risk, romosozumab is conditionally recommended when bisphosphonates are not appropriate, given its dual anabolic and antiresorptive mechanism."

Prescribers in Maine should perform a baseline cardiovascular risk assessment before initiating romosozumab and document this assessment in the medical record. A resting ECG and review of cardiac history should be standard practice, not optional.